In this illustration, the immune cell does not initially recognize the cancer cell. After BiTN particles (red), which include the "eat me" signal (teal), are attached to the cancer cell, the ...

A multifaceted microfluidic in vitro assay is helping to identify the role of hypoxia on red blood cell aging via the biomechanical pathways. It holds promise for investigating hypoxic effects on ...

The test under assessment is a cfDNA blood-based assay for the detection of colorectal cancer. The panel interrogates cfDNA genomic alterations, aberrant methylation status, and fragmentomic patterns.

FORT MYERS, Fla., May 22, 2025--NeoGenomics announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) assay.

The VENTANA MET (SP44) RxDx Assay detects the MET (also known as c-Met) protein, which is over-expressed in some patients with non-squamous non-small cell lung cancer (NSQ-NSCLC).The MET protein ...

PURPOSEMerkel cell carcinoma (MCC) is an aggressive skin cancer with a 40% recurrence rate, lacking effective prognostic biomarkers and surveillance methods. This prospective, multicenter, ...

The test is now available to oncologists and pathologists nationwide, supporting treatment selection for patients with advanced non-small cell lung cancer (NSCLC) with a 48-hour turnaround time.